Objective Measures of Nerve Integrity, Posture, Gait and Blood Flow, After Nerve Decompression (OMNIFICENT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01735903 |
|
Recruitment Status :
Recruiting
First Posted : November 28, 2012
Last Update Posted : February 16, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Diabetic Peripheral Neuropathy | Procedure: Arm A - Non-Diabetic, Gait and Balance |
| Study Type : | Observational |
| Estimated Enrollment : | 40 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Objective Measures of Nerve Integrity, Posture, Gait and Blood Flow, After Nerve Decompression In diabetiC Neuropathy PatiENTs |
| Study Start Date : | November 2012 |
| Estimated Primary Completion Date : | January 2025 |
| Estimated Study Completion Date : | July 2025 |
- Procedure: Arm A - Non-Diabetic, Gait and Balance
Arm A will enroll patients WITHOUT diabetes, but with peripheral neuropathy and lower limb pain, paresthesia, gait disturbances, or motor weakness and will follow the same protocol except the subject will NOT participate in blood flow testing performed at Colorado State University, and therefore do not include the inclusion/exclusion criterion that are specifically related to the blood flow assessment.
Subjects may have any combination of lower limb nerve decompression surgery of the listed surgical sites with or without the addition of Soleal Sling Decompression. Soleal Sling Decompression surgical procedure will require the use of a thigh tourniquet.
- EMG signals used intraoperative as objective measurements of change before and after nerve decompression surgery. Gait, balance and blood flow measurements before and after peripheral nerve decompression surgery [ Time Frame: Within one month of surgical date, surgical date, 3 months and 6 months post operative or 4 months postoperative if the subjects elect to have the contralateral limb surgery prior to 3 months following the initial surgery. ]
Primary Endpoint is assessed by changes in:
- Neuromotor function in the lower limb as measured by intraoperative electromyographic(EMG) recordings of the muscles in the anterior and lateral compartments of the leg and muscles of the foot.
- Blood flow in the lower limb both distal to and proximal to the nerve release sites, as measured by duplex doppler of the external femoral artery (a.), superficial femoral a., popliteal a., anterior and posterior tibial a., dorsal pedis a. Shear stress changes in these arteries.
- Lower limb performance defined as:
- Dorsiflexor strength and speed of contraction
- Proprioception at the ankle
- One-legged standing balance
- Functional reach
- Sensory function in the foot
- Usual gait speed
- Standardized tests of mobility
- Change in sensory perception [ Time Frame: up to one month of surgical date, 3 months and 6 months post operative or 4 months postoperative if the subjects elect to have the contralateral limb surgery prior to 3 months following the initial surgery. ]
- Two-point discrimination
- Changes in nerve conduction measures
- Changes in ankle-brachial index (ABI)
- Visual Analog Score (VAS) for neuropathic symptoms
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patient has been diagnosed with diabetic peripheral neuropathy and has nerve deficit in all proposed surgical areas, sensory and/or motor
- Patient has a positive provocative (i.e. Tinel's sign) observed clinically in the popliteal and tibial nerve trees.
- Patient is between 18 years and 85 years of age
- Patient is a type I or type II diabetic that is currently under medical treatment
- Patient has a Hgb A1C lab value of 8.0% or less
- Patient symptom based VAS scale is 6 or above for at least one of the following: pain, burning, numbness, tingling, weakness or instability
- Patient is scheduled for surgery and has been cleared for outpatient surgery per anesthesia guidelines established for the Foot Surgery Center of Northern Colorado
- Patient is able and willing to comply with all study requirements, including the follow-up evaluations and will return to the investigational site for all required office visits and CSU visits
- Patient has been informed of the nature of the study, agrees to its provisions and has provided written consent
Exclusions Criteria:
- Patient has a BMI of greater than 40 or body weight greater than 300 pounds
- Patient has untreated hypertension (systolic blood pressure > 160 and/or diastolic > 100)
- Patient's ASA is 4 or greater
- Patient has blood glucose greater than 200 the day of surgery
- Patient has Raynaud's Syndrome
- Patient is a current smoker
- Patient is a woman who is considering pregnancy or who is pregnant
- Patient has history of recent nerve or lumbar disc surgery, untreated thyroid disease, B12 or Folate deficiency, hepatic disease, renal disease, and/or Parkinson's disease, or neuropathy due to chemotherapy or radiation therapy
- Patient is being treated with chemotherapeutic agents
- Patient has ankle edema greater than mild - (Moderate to Severe)
- Patient is participating in another investigational device, biologic, or drug study and has not completed the primary endpoint(s) or if there is a potential for clinical interference beyond the primary endpoint
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01735903
| Contact: Megan L Fritz, D.C., M.S. | 479-531-6133 | megan.fritz.dc@gmail.com | |
| Contact: James C Anderson, DPM | 970-484-4620 | janderson@andersonpodiatrycenter.com |
| United States, Colorado | |
| Anderson Podiatry Center, Neuropathy Testing Center of Colorado | Recruiting |
| Fort Collins, Colorado, United States, 80524 | |
| Contact: Megan L Fritz, D.C., M.S. 479-531-6133 megan.fritz.dc@gmail.com | |
| Contact: James C. Anderson, DPM 970-484-4620 janderson@andersonpodiatrycenter.com | |
| Principal Investigator: James C. Anderson, DPM | |
| Principal Investigator: | James C. Anderson, DPM | Anderson Podiatry Center |
| Responsible Party: | James Anderson, DPM, Principal Investigator, Foot Surgery Center of Northern Colorado |
| ClinicalTrials.gov Identifier: | NCT01735903 |
| Other Study ID Numbers: |
OMNI1 |
| First Posted: | November 28, 2012 Key Record Dates |
| Last Update Posted: | February 16, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
|
Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases |

